The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
As China has become the world's second-largest economy and the largest developing country, its economy and market have assumed a prominent position in the Asia-Pacific region. The pharmaceutical industry is an important part of China's national economy, with continuous strong demand, need, and capability for innovation. The industry continues to experience high levels of growth. With China's increasing emphasis on the pharmaceutical industry, and the gradual improvement of healthcare policies, momentum supporting the development of China’s pharmaceutical market continues to accelerate. As the sector’s market structure continues to become more optimized, the Chinese pharmaceutical market as a whole has shown a stable and positive pattern, and its current advantages and future potential are also attracting increasing numbers of overseas companies to do business in China.
This article will analyze the Chinese pharmaceutical market from four aspects: a market overview, the regulatory and reimbursement environment, foreign pharmaceutical companies’ strategies in China, and the current state of innovation adoption.
Related Insights
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Biosimilar reference medicinal product (RMP) regulatory requirements: China, US and EU comparison
Dec 20, 2024
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Related Insights
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Biosimilar reference medicinal product (RMP) regulatory requirements: China, US and EU comparison
Dec 20, 2024
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022